PDF(Pubmed)
Abstract：
AIDS is an incurable disease that is common in Africa. Patients with HIV/AIDS having a CD4 count of less than 240 are put on life prolonging ARV drugs. The ARVs have serious side effects on some patients which may be handled by treating them or switching patient\'s drug to one with no or less serious side effects. However, before doing this, more understanding of the circumstances that lead to a side effect is vital. We use statistical analyses to link side effects of 1A, 2A, and 5A treatment regimens to the patient\'s social and demographic characteristics based on hospital data records. A retrospective review of patients\' master cards (2011-2014) was done to assess adverse effects associated with different ARV regimens. Out of the 901 patients that showed side effects, 65.37% were females aged 31-40 and 34.63% were males. Comparatively, 1A regimen showed more side effects than 2A and 5A regimens. Age, gender and occupation correlated significantly with regimen symptoms (p< 0.05). Unlike men, women had the following extra side effects; cough, peripheral neuropathy and leg pains as compared to lipodystrophy. Our results show that old people (50years+) are less likely to get skin rash and other symptoms compared to lipodystrophy (RRR=0.973). Further, the probability of either having cough (0.0021, p< 0.05), or skin rash (0.0021, p< 0.05), as a side effect, on average, decreases as age increases with the same sex and weight. The probability of having peripheral neuropathy (0.0042, p< 0.01), however, increases with age. Knowledge of HIV patient\'s socio-demographics and the patient\'s regimen side effects can be utilised to appropriately manage severe ARV side effects. A therapy consideration that takes into account chemicals in ARV regimen responsible for specific side effects can be directed to patients with compatible socio-demographic characteristics.
摘要：
艾滋病是一种不治之症，在非洲很常见。CD4计数低于240的HIV/AIDS患者应服用延长寿命的ARV药物。抗逆转录病毒药物对一些患者有严重的副作用，可以通过治疗或将患者的药物转换为没有或没有严重副作用的药物来处理。然而,在这样做之前，更多地了解导致副作用的情况是至关重要的。我们使用统计分析来联系1A的副作用，2A,根据医院数据记录，根据患者的社会和人口统计学特征制定5A治疗方案。对患者主卡（2011-2014）进行回顾性审查，以评估与不同ARV方案相关的不良反应。在901名出现副作用的患者中，31-40岁女性占65.37%，男性占34.63%。相对而言,1A方案显示比2A和5A方案更多的副作用。年龄,性别和职业与治疗方案症状显著相关(p<0.05)。不像男人,女性有以下额外的副作用；咳嗽，与脂肪营养不良相比，周围神经病变和腿部疼痛。我们的结果表明，与脂肪营养不良相比，老年人（50岁以上）不太可能出现皮疹和其他症状（RRR=0.973）。Further,咳嗽的概率(0.0021，p<0.05)，或皮疹（0.0021，p<0.05），作为副作用，平均而言,随着年龄的增加，性别和体重相同。周围神经病变的概率（0.0042，p<0.01），然而,随着年龄的增长。了解HIV患者的社会人口统计学和患者的治疗方案副作用可用于适当管理严重的ARV副作用。考虑到ARV方案中导致特定副作用的化学物质的治疗考虑可以针对具有相容的社会人口统计学特征的患者。
